Recordati Industria Chimica e Farmaceutica (REC) Stock Overview
Researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
REC Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Recordati Industria Chimica e Farmaceutica S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €47.90 |
| 52 Week High | €60.30 |
| 52 Week Low | €43.98 |
| Beta | 0.61 |
| 1 Month Change | -0.99% |
| 3 Month Change | -9.28% |
| 1 Year Change | -19.63% |
| 3 Year Change | 16.55% |
| 5 Year Change | 9.36% |
| Change since IPO | 3,586.88% |
Recent News & Updates
Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Trading At A 29% Discount?
Jan 17
Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Price In Tune With Earnings
Dec 19Recent updates
Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Trading At A 29% Discount?
Jan 17Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Price In Tune With Earnings
Dec 19Analysts Have Made A Financial Statement On Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Third-Quarter Report
Nov 15Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Oct 28Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Price Is Out Of Tune With Earnings
Sep 09We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings
Aug 08Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 5.4% And Analysts Are Revising Their Forecasts
Aug 04Does Recordati Industria Chimica e Farmaceutica (BIT:REC) Have A Healthy Balance Sheet?
Jul 13Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.67
May 09Here's Why Shareholders May Consider Paying Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) CEO A Little More
Apr 22Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 16Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.67
Mar 22Is Now The Time To Put Recordati Industria Chimica e Farmaceutica (BIT:REC) On Your Watchlist?
Mar 19
Calculated Acquisitions And Market Expansions Set The Stage For Robust Financial Growth
Strategic acquisitions and market expansions enhance revenue growth, especially the rights to Enjaymo and early Isturisa approval in China.Shareholder Returns
| REC | IT Pharmaceuticals | IT Market | |
|---|---|---|---|
| 7D | 1.5% | 2.9% | -0.9% |
| 1Y | -19.6% | 7.6% | 18.8% |
Return vs Industry: REC underperformed the Italian Pharmaceuticals industry which returned 5.1% over the past year.
Return vs Market: REC underperformed the Italian Market which returned 20.5% over the past year.
Price Volatility
| REC volatility | |
|---|---|
| REC Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 6.9% |
| 10% least volatile stocks in IT Market | 2.6% |
Stable Share Price: REC has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: REC's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 4,539 | Rob Koremans | recordati.com |
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing’s syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fortivda for renal cell carcinoma.
Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary
| REC fundamental statistics | |
|---|---|
| Market cap | €9.80b |
| Earnings (TTM) | €404.39m |
| Revenue (TTM) | €2.55b |
Is REC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REC income statement (TTM) | |
|---|---|
| Revenue | €2.55b |
| Cost of Revenue | €788.74m |
| Gross Profit | €1.77b |
| Other Expenses | €1.36b |
| Earnings | €404.39m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 17, 2026
| Earnings per share (EPS) | 1.98 |
| Gross Margin | 69.13% |
| Net Profit Margin | 15.83% |
| Debt/Equity Ratio | 127.9% |
How did REC perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 15:34 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 26 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paola Saglietti | Banca Akros S.p.A. (ESN) |
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |